FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162277331> ?p ?o ?g. }

• W3162277331 endingPage "2109" @default.
• W3162277331 startingPage "2099" @default.
• W3162277331 abstract "The aim of this study is to evaluate eye structures and function in patients receiving iron chelating therapy and to assess whether a correlation exists between the onset of ocular alterations and the intake of iron chelating drugs.A prospective cohort study was performed. Eighty-eight patients, composed of children and adults with thalassemia major (TM) who are taking or had taken iron chelating drugs (deferoxamine, deferiprone or deferasirox), have been initially enrolled in the study. The final sample featured 80 patients, including 18 children and 62 adults. These subjects received an eye examination to evaluate intraocular pressure (IOP), best corrected visual acuity (BCVA), the presence of refractive defects, cornea, anterior chamber, lens, fundus oculi, visual field and mean retinal nerve fiber layer (RNFL) thickness. Logistic regression model analysis was performed in order to assess any correlation. In addition, a literature search regarding the relation between iron chelating drugs and ocular adverse events was carried out to compare the results obtained with the evidence in the literature.Logistic regression did not report a significant correlation between the intake of iron chelating drugs and the onset of anterior ocular segment alterations, lens opacities, retinal diseases, optical neuropathies, astigmatism, visual field and RNFL thickness defects. Logistic regression returned a statistically significant correlation between myopia and iron chelation therapy (p-value 0.04; OR 1.05) and also between presbyopia and total duration of therapy with deferoxamine (p-value 0.03; OR 1.21). Although intraocular pressure levels remained within the normal range, a significant correlation with the length of deferoxamine therapy has been found (p-value 0.002; association coefficient -0.12). A negative correlation between deferiprone and presbyopia has also been observed.Iron chelation therapy is not associated with severe visual function alterations. Limitation of deferoxamine treatment can help prevent ocular complications. Deferiprone and/or deferasirox may be preferable, especially in patients over age 40 years." @default.
• W3162277331 created "2021-05-24" @default.
• W3162277331 creator A5029281593 @default.
• W3162277331 creator A5042871700 @default.
• W3162277331 creator A5051452439 @default.
• W3162277331 creator A5052769414 @default.
• W3162277331 creator A5066722763 @default.
• W3162277331 creator A5082739991 @default.
• W3162277331 date "2021-05-01" @default.
• W3162277331 modified "2023-09-23" @default.
• W3162277331 title "Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major" @default.
• W3162277331 cites W1492995138 @default.
• W3162277331 cites W1939359716 @default.
• W3162277331 cites W1946557302 @default.
• W3162277331 cites W1958668304 @default.
• W3162277331 cites W1965601064 @default.
• W3162277331 cites W1967989899 @default.
• W3162277331 cites W1973040032 @default.
• W3162277331 cites W1974664679 @default.
• W3162277331 cites W1981246054 @default.
• W3162277331 cites W1983372029 @default.
• W3162277331 cites W1983607584 @default.
• W3162277331 cites W1989595223 @default.
• W3162277331 cites W1990752141 @default.
• W3162277331 cites W1997376718 @default.
• W3162277331 cites W2005969591 @default.
• W3162277331 cites W2006731329 @default.
• W3162277331 cites W2007615180 @default.
• W3162277331 cites W2019760194 @default.
• W3162277331 cites W2026158878 @default.
• W3162277331 cites W2031683173 @default.
• W3162277331 cites W2032182561 @default.
• W3162277331 cites W2045075671 @default.
• W3162277331 cites W2046178109 @default.
• W3162277331 cites W2051260674 @default.
• W3162277331 cites W2058681934 @default.
• W3162277331 cites W2078044428 @default.
• W3162277331 cites W2081084007 @default.
• W3162277331 cites W2087565152 @default.
• W3162277331 cites W2088372596 @default.
• W3162277331 cites W2089876393 @default.
• W3162277331 cites W2093011620 @default.
• W3162277331 cites W2101352360 @default.
• W3162277331 cites W2109853368 @default.
• W3162277331 cites W2114400437 @default.
• W3162277331 cites W2118011250 @default.
• W3162277331 cites W2132381451 @default.
• W3162277331 cites W2151869002 @default.
• W3162277331 cites W2163004607 @default.
• W3162277331 cites W2165897391 @default.
• W3162277331 cites W2270455336 @default.
• W3162277331 cites W2328280316 @default.
• W3162277331 cites W2335045642 @default.
• W3162277331 cites W2417576728 @default.
• W3162277331 cites W2438856471 @default.
• W3162277331 cites W2490341890 @default.
• W3162277331 cites W2513337309 @default.
• W3162277331 cites W2523555672 @default.
• W3162277331 cites W2558931807 @default.
• W3162277331 cites W2597600938 @default.
• W3162277331 cites W2603099192 @default.
• W3162277331 cites W3187992181 @default.
• W3162277331 cites W4237708983 @default.
• W3162277331 cites W4242681729 @default.
• W3162277331 doi "https://doi.org/10.2147/opth.s300974" @default.
• W3162277331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8144174" @default.
• W3162277331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34045846" @default.
• W3162277331 hasPublicationYear "2021" @default.
• W3162277331 type Work @default.
• W3162277331 sameAs 3162277331 @default.
• W3162277331 citedByCount "5" @default.
• W3162277331 countsByYear W31622773312021 @default.
• W3162277331 countsByYear W31622773312022 @default.
• W3162277331 countsByYear W31622773312023 @default.
• W3162277331 crossrefType "journal-article" @default.
• W3162277331 hasAuthorship W3162277331A5029281593 @default.
• W3162277331 hasAuthorship W3162277331A5042871700 @default.
• W3162277331 hasAuthorship W3162277331A5051452439 @default.
• W3162277331 hasAuthorship W3162277331A5052769414 @default.
• W3162277331 hasAuthorship W3162277331A5066722763 @default.
• W3162277331 hasAuthorship W3162277331A5082739991 @default.
• W3162277331 hasBestOaLocation W31622773311 @default.
• W3162277331 hasConcept C118487528 @default.
• W3162277331 hasConcept C126322002 @default.
• W3162277331 hasConcept C188816634 @default.
• W3162277331 hasConcept C2776391266 @default.
• W3162277331 hasConcept C2776517179 @default.
• W3162277331 hasConcept C2777218474 @default.
• W3162277331 hasConcept C2777799968 @default.
• W3162277331 hasConcept C2778257484 @default.
• W3162277331 hasConcept C2778527774 @default.
• W3162277331 hasConcept C2780592520 @default.
• W3162277331 hasConcept C2780827179 @default.
• W3162277331 hasConcept C2781053155 @default.
• W3162277331 hasConcept C2781092963 @default.
• W3162277331 hasConcept C71924100 @default.
• W3162277331 hasConceptScore W3162277331C118487528 @default.
• W3162277331 hasConceptScore W3162277331C126322002 @default.

• next